Neratinib therapy targeting EGFR / ERBB2 receptors in hormone receptor-positive / HER2-negative and HER2-enriched metastatic breast cancer
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SOLTI
- Phase: II
- Execution start: 30/06/2020
- End of execution: 30/06/2024
- IP: ISABEL BLANCAS LOPEZ-BARAJAS
